Literature DB >> 17131134

Does trazodone have a role in palliating symptoms?

Mellar P Davis1.   

Abstract

INTRODUCTION: Trazodone is a unique antidepressant, which blocks the postsynaptic serotonin (5-HT) receptors, 5-HT(2A) and 5-HT(2C), and weakly inhibits presynaptic 5-HT transporters. DISCUSSION: Trazodone is well-absorbed by the mouth and is metabolized by three cytochromes: CYP1A2, CYP2D6, and CYP3A4. Clinical benefits include reduced insomnia in those depressed and/or on antidepressants. Pain may be relieved by mechanisms similar to venlafaxine. Delirium unresponsive to neuroleptics has been reported to respond to trazodone. Drug interactions are a risk due to cytochrome metabolism.
CONCLUSION: Trazodone has a unique pharmacology, which may be an advantage in palliating symptoms; however, little evidence is available through cohort or randomized trials to give guidance to its use.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17131134     DOI: 10.1007/s00520-006-0111-0

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  33 in total

1.  Effects of trazodone and fluoxetine in the treatment of major depression: therapeutic pharmacokinetic and pharmacodynamic interactions through formation of meta-chlorophenylpiperazine.

Authors:  M Maes; H Westenberg; E Vandoolaeghe; P Demedts; A Wauters; H Neels; H Y Meltzer
Journal:  J Clin Psychopharmacol       Date:  1997-10       Impact factor: 3.153

2.  The antinociceptive effect of trazodone in mice is mediated through both mu-opioid and serotonergic mechanisms.

Authors:  S Schreiber; M M Backer; I Herman; D Shamir; T Boniel; C G Pick
Journal:  Behav Brain Res       Date:  2000-09       Impact factor: 3.332

3.  Increases in plasma concentration of m-chlorophenylpiperazine, but not trazodone, with low-dose haloperidol.

Authors:  K Mihara; K Otani; M Ishida; N Yasui; A Suzuki; T Ohkubo; T Osanai; S Kaneko; K Sugawara
Journal:  Ther Drug Monit       Date:  1997-02       Impact factor: 3.681

4.  Pharmacokinetics of trazodone and its major metabolite m-chlorophenylpiperazine in plasma and brain of rats.

Authors:  C. Lindsay DeVane; David W. Boulton; Lisa F. Miller; Ronald L. Miller
Journal:  Int J Neuropsychopharmacol       Date:  1999-03       Impact factor: 5.176

5.  Relationship between plasma concentrations of trazodone and its active metabolite, m-chlorophenylpiperazine, and its clinical effect in depressed patients.

Authors:  Kazuo Mihara; Norio Yasui-Furukori; Tsuyoshi Kondo; Masayuki Ishida; Shingo Ono; Tadashi Ohkubo; Takako Osanai; Kazunobu Sugawara; Koichi Otani; Sunao Kaneko
Journal:  Ther Drug Monit       Date:  2002-08       Impact factor: 3.681

6.  The effects of trazodone on sleep in patients treated with stimulant antidepressants.

Authors:  Hakan Kaynak; Derya Kaynak; Erbil Gözükirmizi; Christian Guilleminault
Journal:  Sleep Med       Date:  2004-01       Impact factor: 3.492

7.  Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources.

Authors:  S Rotzinger; J Fang; G B Baker
Journal:  Drug Metab Dispos       Date:  1998-06       Impact factor: 3.922

8.  Trazodone is a potent agonist at 5-HT2C receptors mediating inhibition of the N-methyl-D-aspartate/nitric oxide/cyclic GMP pathway in rat cerebellum.

Authors:  M Marcoli; G Maura; M Tortarolo; M Raiteri
Journal:  J Pharmacol Exp Ther       Date:  1998-06       Impact factor: 4.030

Review 9.  Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders.

Authors:  M Haria; A Fitton; D McTavish
Journal:  Drugs Aging       Date:  1994-04       Impact factor: 3.923

10.  Trazodone hydrochloride attenuates thermal hyperalgesia in a chronic constriction injury rat model.

Authors:  K Okuda; T Takanishi; K Yoshimoto; S Ueda
Journal:  Eur J Anaesthesiol       Date:  2003-05       Impact factor: 4.330

View more
  5 in total

Review 1.  Management of delirium in palliative care: a review.

Authors:  Luigi Grassi; Augusto Caraceni; Alex J Mitchell; Maria Giulia Nanni; Maria Alejandra Berardi; Rosangela Caruso; Michelle Riba
Journal:  Curr Psychiatry Rep       Date:  2015-03       Impact factor: 5.285

2.  Is depression an appropriate response to having cancer? A discussion of diagnostic criteria and treatment decisions.

Authors:  Anne F Gross; Felicia A Smith; Theodore A Stern
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007

3.  Antidepressants appear safe in patients with carcinoid tumor: Results of a retrospective review.

Authors:  Elie Isenberg-Grzeda; Meredith MacGregor; Afton Bergel; Stacy Eagle; Fernando Espi Forcen; Reema Mehta; Konstantina Matsoukas; Jonathan Wills; Diane Reidy-Lagunes; Yesne Alici
Journal:  Eur J Surg Oncol       Date:  2018-03-21       Impact factor: 4.424

Review 4.  Delirium in older adults.

Authors:  Dennis M Popeo
Journal:  Mt Sinai J Med       Date:  2011 Jul-Aug

Review 5.  Pharmacological management of depression in patients with cancer: practical considerations.

Authors:  Riccardo G V Torta; Valentina Ieraci
Journal:  Drugs       Date:  2013-07       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.